Primary Objective:
      To evaluate the safety and tolerability of olipudase alfa administered intravenously in
      pediatric patients every 2 weeks for 52 weeks.
      Secondary Objective:
      To characterize the pharmacokinetic profile and evaluate the pharmacodynamics and exploratory
      efficacy of olipudase alfa administered intravenously in pediatric patients every 2 weeks for
      52 weeks.
    
  
Primary Outcomes 
 Measure: Number of adverse events Time: From screening through Week 64
 Measure: Clinically significant changes in laboratory parameters (complete blood count (CBC), clinical chemistry, and urinalysis) Time: From screening through Week 64
 Measure: Clinically significant changes in physical examinations (vital signs, electrocardiogram (ECG), doppler echocardiography, and liver ultrasound doppler) Time: From screening through Week 64
   
Secondary Outcomes 
 Measure: Maximum concentration (Cmax) Time: With the first infusion at 0.3, 1.0 and 3.0 mg/kg and at Week 52
 Measure: Area under the curve until the last measurable concentration (AUClast) Time: With the first infusion at 0.3, 1.0 and 3.0 mg/kg and at Week 52
 Measure: Area under the curve extrapolated to infinity (AUC) Time: With the first infusion at 0.3, 1.0 and 3.0 mg/kg and at Week 52
 Measure: Half-life (t1/2) Time: With the first infusion at 0.3, 1.0 and 3.0 mg/kg and at Week 52
 Measure: Clearance (CL) Time: With the first infusion at 0.3, 1.0 and 3.0 mg/kg and at Week 52
 Measure: Volume of distribution (Vss) Time: With the first infusion at 0.3, 1.0 and 3.0 mg/kg and at Week 52
 Measure: Change in sphingomyelin levels Time: From Day 1 through Week 64
 Measure: Change in sphingomyelin metabolite levels Time: From Day 1 through Week 64